Nasdaq
华尔街日报Clay Siegall Bought 5.8% More Shares In Immunome
Those following along with Immunome, Inc. (NASDAQ:IMNM) will no doubt be intrigued by the recent purchase of shares by Clay Siegall, Chairman of the company, who spent a stonking US$1m on stock at an average price of US$21.50. While that only increased their holding size by 5.8%, it is still a big swing by our standards.
Immunome Insider Transactions Over The Last Year
Notably, that recent purchase by Chairman Clay Siegall was not the only time they bought Immunome shares this year. They previously made an even bigger purchase of US$1.2m worth of shares at a price of US$7.75 per share. We do like to see buying, but this purchase was made at well below the current price of US$21.44. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
Immunome insiders may have bought shares in the last year, but they didn't sell any. Their average price was about US$9.38. To my mind it is good that insiders have invested their own money in the company. However, we do note that they were buying at significantly lower prices than today's share price. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Check out our latest analysis for Immunome
There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership
Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Immunome insiders own about US$38m worth of shares. That equates to 2.1% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
So What Does This Data Suggest About Immunome Insiders?
The recent insider purchase is heartening. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Given that insiders also own a fair bit of Immunome we think they are probably pretty confident of a bright future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Be aware that Immunome is showing 3 warning signs in our investment analysis, and 1 of those is concerning...
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.